Press releases

8 February 2017

Result of General Meeting Consolidation of Share Capital

8 February 2017, London – Verona Pharma plc (AIM: VRP), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, announces that all reso…

Read more

18 January 2017

Shareholder Circular for proposed consolidation, authority to issue new shares, adoption of new Articles and Notice of Meeting on 8 February 2017

Download the 'Shareholder Circular for proposed consolidation, authority to issue new shares, adoption of new Articles and Notice of Meeting on 8 February 2017' by clicking here or by visiting our download centre here.

Read more

18 January 2017

Proposed new Articles for adoption at Meeting on 8 February 2017

Download the 'Proposed new Articles for adoption at Meeting on 8 February 2017' by clicking here, or from our download centre here.

Read more

23 November 2016

Verona Pharma plans to conduct registered Initial Public Offering in the U.S.

Verona Pharma plc (AIM: VRP) today announced that it plans to conduct a registered initial public offering in the United States. The number of shares and price of the proposed offering have not yet been determined. The proposed offering is expected to commence in the fi…

Read more

26 October 2016

Verona Pharma receives second Venture and Innovation Award from the Cystic Fibrosis Trust

Supports first clinical study in patients to explore potential for RPL554 as a novel treatment for cystic fibrosis

Read more

30 August 2016

New clinical data on RPL554 to be presented at the 2016 ERS International Congress

Detailed data from Phase 2a “add-on” trial as “LATE-BREAKING abstract”

Read more

10 May 2016

Verona Pharma announces positive results from “add-on” Phase II trial with RPL554

RPL554 produced over 60% additional bronchodilation on top of standard of care bronchodilators in COPD patients Data implies RPL554, alone or in combination with other bronchodilators, may reduce dyspnea, a major debilitating symptom of COPD

Read more

4 May 2016

Verona to present clinical data on RPL554 at the ATS International Conference

04 May 2016, Cardiff – Verona Pharma plc (AIM: VRP.L), the drug development company focused on first- in-class medicines to treat respiratory diseases, today announces that it will present three abstracts at the American Thoracic Society (ATS) 2016 Internationa…

Read more

15 March 2016

Verona Pharma reports positive results from RPL554 dose-finding study

Study demonstrates drug has substantial bronchodilator effect and excellent tolerability at broad range of doses

Read more

11 November 2015

Paper demonstrating that RPL554 enhances CTFR activation in cystic fibrosis airway epithelia published in American Journal of Physiology

11 November 2015, Cardiff – Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respiratory diseases, announces that a paper examining the effect of Verona Pharma’s dual PDE3/4 inhibitor, RPL554, on the Cys…

Read more

Realising multiple value creation opportunities with a unique respiratory product RPL554

AGM presentation

27 June 2016

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Targeting unmet needs

210m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us